Medivir: Positive Phase II Results, Still Unclear Outlook for Skin Oncology Asset
Bildkälla: Stockfoto

Medivir: Positive Phase II Results, Still Unclear Outlook for Skin Oncology Asset

Redeye comments on the positive update for remetinostat in basal cell carcinoma.

Börsvärldens nyhetsbrev